Provided by Tiger Fintech (Singapore) Pte. Ltd.

iTeos Therapeutics

6.80
-0.0500-0.73%
Volume:62.75K
Turnover:421.83K
Market Cap:260.26M
PE:-2.20
High:6.87
Open:6.79
Low:6.61
Close:6.85
Loading ...

Iteos Therapeutics Inc Qtrly Net Loss of $1.01 per Basic and Diluted Share

THOMSON REUTERS
·
05 Mar

Iteos Therapeutics Inc Q4 Shr View $-1.06 -- Lseg Ibes Data

THOMSON REUTERS
·
05 Mar

Press Release: iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Dow Jones
·
05 Mar

iTeos Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Jan

All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy

Zacks
·
14 Jan

iTeos Therapeutics Plans 2025 Data Presentation on Therapies

TIPRANKS
·
13 Jan

Iteos Therapeutics Inc - Eos-984 Phase 1 Monotherapy and Pd-1 Combination Data Expected in 2H25

THOMSON REUTERS
·
10 Jan

Iteos Therapeutics Inc - Cash Balance of $683.9 Million Expected to Provide Runway Through 2027

THOMSON REUTERS
·
10 Jan

Iteos Therapeutics Inc - Eos-215 Ind Submission Anticipated in 1Q25

THOMSON REUTERS
·
10 Jan

Iteos Announces 2025 Strategic Priorities and Anticipated Milestones

THOMSON REUTERS
·
10 Jan

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

GlobeNewswire
·
10 Jan

iTeos Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
19 Dec 2024

iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

TIPRANKS
·
19 Dec 2024

iTeos Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Dec 2024

Iteos Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $21 From $46

THOMSON REUTERS
·
13 Dec 2024

Iteos Therapeutics Inc : Piper Sandler Cuts Target Price to $16 From $36

THOMSON REUTERS
·
13 Dec 2024

iTeos Therapeutics Says Deprioritizing Cancer Drug Candidate Inupadenant

MT Newswires Live
·
12 Dec 2024

iTeos Therapeutics presents interim A2A-005 clinical trial data

TIPRANKS
·
12 Dec 2024

Iteos Therapeutics Presents Interim a2a-005 Clinical Trial Data, Translational, and Preclinical Data From Inupadenant at Esmo Immuno-Oncology Congress

THOMSON REUTERS
·
12 Dec 2024

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

GlobeNewswire
·
12 Dec 2024